XLR-12 is an indole-based synthetic cannabinoid drug that was invented by Abbott Laboratories in 2006. It is an analogue of XLR-11 where the 5-fluoropentyl chain has been replaced with a 4,4,4-trifluorobutyl chain. XLR-12 is relatively highly selective for the CB<sub>2</sub> receptor, with a K<sub>i</sub> of 0.09 nM and 167x selectivity over the related CB<sub>1</sub> receptor, however it still retains appreciable affinity for CB<sub>1</sub> with a K<sub>i</sub> of 15 nM.
XLR-12 is illegal in Hungary and Japan.